Mid-regional proadrenomedullin (MR-proADM), C-reactive protein (CRP) and other biomarkers in the early identification of disease progression in patients with COVID-19 in the acute NHS setting

Conclusions The measurement of MR-proADM and CRP in patients with confirmed COVID-19 infection on admission shows significant potential to support clinicians in identifying those at increased risk of disease progression and need for higher level care, subsequently enabling prompt escalation in clinical interventions.

http://jcp.bmj.com/cgi/content/short/76/6/400?rss=1

Source: Journal of Clinical Pathology - May 18, 2023 Category: Pathology Authors: Moore, N., Williams, R., Mori, M., Bertolusso, B., Vernet, G., Lynch, J., Philipson, P., Ledgerwood, T., Kidd, S. P., Thomas, C., Garcia-Arias, V., Young, M., Saeed, K., Gordon, K., Cortes, N. Tags: COVID-19 Original research Source Type: research